首页 | 本学科首页   官方微博 | 高级检索  
检索        

康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究
引用本文:付红星,冯小剑,彭文苗,饶智国.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,0(24):115-117.
作者姓名:付红星  冯小剑  彭文苗  饶智国
作者单位:1.湖北中医药大学第一临床学院,湖北 武汉 430061;2.解放军武汉总医院,湖北 武汉 430070
摘    要:目的 探讨康艾注射液配合多西他赛、顺铂治疗晚期非小细胞肺癌的客观疗效和安全性。方法 将解放军武汉总医院2015年2月~2018 年2月收治的100例晚期非小细胞肺癌患者按随机数字表法分为两组,每组50例。对照组给予多西他赛、顺铂化疗,治疗组在对照组基础上加康艾注射液治疗。连续治疗2个疗程后评估疗效、生活质量、中医症状和不良反应。结果 治疗组的有效率为46.00%,高于照组的44.00%,但差异无统计学意义(P>0.05);治疗组在生活质量改善优于对照组(68.00% vs 48.00%)(P<0.05)。治疗组纳呆、神疲乏力、呕吐三组中医症状均较对照组有改善(P<0.05)。治疗组化疗不良反应减轻方面优于对照组(P<0.05)。结论 康艾注射液联合多西他赛、顺铂治疗晚期非小细胞肺癌在稳定性、改善生活质量、减轻毒副反应方面存在一定优势,值得进一步深入研究。

关 键 词:康艾注射液  联合化疗  非小细胞肺癌  生存质量

Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer
FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,RAO Zhi-guo.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,0(24):115-117.
Authors:FU Hong-xing  FENG Xiao-jian  PENG Wen-miao  RAO Zhi-guo
Institution:1.First clinical college of Hubei University of Traditional Chinese Medicine,Wuhan 430061,Hubei,China;2.PLA Wuhan General Hospital,Wuhan 430070,Hubei,China
Abstract:Objective To investigate the efficacy and safety of Kang'ai injection combined with docetaxel and cisplatin in the treatment of advanced non-small cell lung cancer. Methods 100 patients with advanced non-small cell lung cancer treated in PLA Wuhan General Hospital from February 2015 to February 2018 were divided into control group and treatment group according to the method of random digital table, 50 cases in each group.The control group was treated with docetaxel and cisplatin, and the treatment group was treated with Kang'ai injection on the basis of the control group.We evaluated the efficacy, quality of life, TCM symptoms and adverse reactions after 2 consecutive courses of treatment.Results The effective rate of the treatment group was 46.00%, which was higher than that of the radiation group 44.00%, but the difference was not statistically significant(P>0.05).The improvement of quality of life in the treatment group was better than that in the control group (68. 00% vs 48. 00%) (P<0. 05).The symptoms of TCM in the treatment group were improved compared with the control group(P<0.05). The side effect of chemotherapy in the treatment group was better than that in the control group(P<0.05).Conclusion Kang'ai injection combined with docetaxel and cisplatin in the treatment of advanced non-small cell lung cancer has some advantages in terms of stability, improving quality of life and alleviating side effects, which is worthy of further study.
Keywords:Kang'ai Injection  Non-small cell lung cancer  Quality of life
点击此处可从《医学信息》浏览原始摘要信息
点击此处可从《医学信息》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号